排序方式: 共有3条查询结果,搜索用时 0 毫秒
1
1.
The current enthusiasm for pharmacogenetics draws much of its inspiration from the relatively few examples of polymorphisms that have marked and seemingly clinically relevant effects on drug response. In this regard, pharmacogenetic research has paralleled the study of human disease, which has enjoyed success in identifying mutations underlying mendelian conditions. Progress in deciphering the genetics of complex diseases, involving the interaction of multiple genes with each other and with the environment has been considerably less successful. In most instances, drug responses will probably also prove to be complex, influenced by both the environment and multiple genetic factors. For pharmacogenetics to deliver on its potential, this complexity will need to be recognized and accommodated, both in basic research and in clinical application of pharmacogenetics. As the attention of researchers begins to shift toward more systematic pharmacogenetic investigations, we suggest some priorities and standards for pharmacogenetic research. 相似文献
2.
3.
Large recurrent microdeletions associated with schizophrenia 总被引:1,自引:0,他引:1
Stefansson H Rujescu D Cichon S Pietiläinen OP Ingason A Steinberg S Fossdal R Sigurdsson E Sigmundsson T Buizer-Voskamp JE Hansen T Jakobsen KD Muglia P Francks C Matthews PM Gylfason A Halldorsson BV Gudbjartsson D Thorgeirsson TE Sigurdsson A Jonasdottir A Jonasdottir A Bjornsson A Mattiasdottir S Blondal T Haraldsson M Magnusdottir BB Giegling I Möller HJ Hartmann A Shianna KV Ge D Need AC Crombie C Fraser G Walker N Lonnqvist J Suvisaari J Tuulio-Henriksson A Paunio T Toulopoulou T 《Nature》2008,455(7210):232-236
Reduced fecundity, associated with severe mental disorders, places negative selection pressure on risk alleles and may explain, in part, why common variants have not been found that confer risk of disorders such as autism, schizophrenia and mental retardation. Thus, rare variants may account for a larger fraction of the overall genetic risk than previously assumed. In contrast to rare single nucleotide mutations, rare copy number variations (CNVs) can be detected using genome-wide single nucleotide polymorphism arrays. This has led to the identification of CNVs associated with mental retardation and autism. In a genome-wide search for CNVs associating with schizophrenia, we used a population-based sample to identify de novo CNVs by analysing 9,878 transmissions from parents to offspring. The 66 de novo CNVs identified were tested for association in a sample of 1,433 schizophrenia cases and 33,250 controls. Three deletions at 1q21.1, 15q11.2 and 15q13.3 showing nominal association with schizophrenia in the first sample (phase I) were followed up in a second sample of 3,285 cases and 7,951 controls (phase II). All three deletions significantly associate with schizophrenia and related psychoses in the combined sample. The identification of these rare, recurrent risk variants, having occurred independently in multiple founders and being subject to negative selection, is important in itself. CNV analysis may also point the way to the identification of additional and more prevalent risk variants in genes and pathways involved in schizophrenia. 相似文献
1